GLAXOSMITHKLINE (GSK) is to sell its Horlicks drinks brand in the UK and shut its Slough manufacturing site, as well as abandoning a planned new biopharmaceutical site in Ulverston as part of a number of changes.
In a statement the company said that it is making the changes as part of efforts to improve efficiency and competitiveness. GSK will also carry out a strategic review of its UK cephalosporins antibiotics business and may sell some of the associated manufacturing facilities in Ulverston, Barnard Castle and Verona in Italy. Some of the manufacturing at its Worthing site will be outsourced. GSK says that it expects around 320 jobs to be lost as a result of the Slough closure and outsourcing plans over the next four years. As well as Horlicks, GSK plans to sell its MaxiNutrition brand in the UK and may sell other non-core brands.